| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/BF03346373 |
| P698 | PubMed publication ID | 18475058 |
| P2093 | author name string | Rossi A | |
| Valle D | |||
| Gentilella R | |||
| Pitocco D | |||
| P2860 | cites work | Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes | Q28212600 | ||
| Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial | Q28277510 | ||
| Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 | ||
| Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats | Q28578709 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year | Q33220335 | ||
| Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association | Q33728882 | ||
| Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs | Q33984638 | ||
| Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention | Q34319528 | ||
| Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis | Q34530843 | ||
| Standards of medical care in diabetes--2007. | Q34595288 | ||
| Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis | Q34634794 | ||
| Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes | Q35634210 | ||
| Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus | Q35894298 | ||
| Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. | Q36519973 | ||
| Rationale for the association of sulfonylurea and insulin | Q37250623 | ||
| Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study | Q39518005 | ||
| Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes | Q40404408 | ||
| Glucagon-like peptide-1 prevents beta cell glucolipotoxicity | Q40565084 | ||
| The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy | Q42462041 | ||
| Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure | Q43517707 | ||
| Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro | Q43586628 | ||
| Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial | Q43606926 | ||
| Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). | Q44333619 | ||
| Deteriorating beta-cell function in type 2 diabetes: a long-term model | Q44372257 | ||
| Secondary sulphonylurea failure: what pathogenesis is responsible? | Q44393625 | ||
| Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial | Q44479625 | ||
| Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure. | Q44584834 | ||
| The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients | Q44631767 | ||
| Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies | Q44698439 | ||
| Short-term intensive insulin therapy in newly diagnosed type 2 diabetes | Q44865579 | ||
| Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial | Q44909518 | ||
| Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk | Q45069543 | ||
| Sulfonylurea induced beta-cell apoptosis in cultured human islets | Q45105959 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes | Q46401178 | ||
| Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes | Q46458837 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus | Q46520634 | ||
| A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia | Q46570674 | ||
| Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. | Q46849874 | ||
| Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study | Q46913091 | ||
| C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. | Q47299422 | ||
| Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes | Q47317632 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. | Q51468797 | ||
| The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. | Q51473976 | ||
| Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. | Q51478119 | ||
| A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. | Q51483637 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. | Q51483804 | ||
| Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure. | Q51559826 | ||
| UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. | Q51570043 | ||
| Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. | Q51572651 | ||
| Insulin versus a combination of insulin and sulfonylurea in the treatment of NIDDM patients with secondary oral failure. | Q51585166 | ||
| Twice daily insulin therapy in patients with type 2 diabetes and secondary failure to sulphonylureas. | Q51617090 | ||
| Sex differences in the coronary heart disease risk profile: a possible role for insulin. The Beaver County Study. | Q51630050 | ||
| Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells. | Q53544467 | ||
| Glycosylated Hemoglobin: Finally Ready for Prime Time as a Cardiovascular Risk Factor | Q58040332 | ||
| Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes | Q60722739 | ||
| In search of normoglycaemia in diabetes: controlling postprandial glucose | Q61684861 | ||
| Morning or bedtime NPH insulin combined with sulfonylurea in treatment of NIDDM | Q68032842 | ||
| [Combination therapy with sulfonylurea plus insulin in "secondary failure" of type 2 diabetes] | Q68932561 | ||
| Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up | Q71338245 | ||
| Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) | Q73095398 | ||
| The utility of postprandial C-peptide evaluation in type 2 diabetes | Q73490316 | ||
| The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management--2000 update | Q74104627 | ||
| When oral agents fail: practical barriers to starting insulin | Q74601463 | ||
| Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial | Q78069268 | ||
| [Commentary to the article: Kahn SE, Haffner SM, Heise MA, et al. ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43] | Q79967063 | ||
| P433 | issue | 4 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 371-379 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Journal of Endocrinological Investigation | Q15766847 |
| P1476 | title | Unmet needs among patients with type 2 diabetes and secondary failure to oral anti-diabetic agents | |
| P478 | volume | 31 |
| Q46325597 | Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. |
| Q38364806 | Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer. |
| Q90169537 | Cultural adaptation of a patient decision-aid for insulin therapy |
| Q51362072 | Factors that influence basal insulin requirement in type 2 diabetes. |
Search more.